292 related articles for article (PubMed ID: 28947035)
1. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
3. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
5. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
6. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
[TBL] [Abstract][Full Text] [Related]
7. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
[TBL] [Abstract][Full Text] [Related]
9. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
10. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.
Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J
BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553
[TBL] [Abstract][Full Text] [Related]
11. Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV
Nagy B; Bene Z; Fejes Z; Heltshe SL; Reid D; Ronan NJ; McCarthy Y; Smith D; Nagy A; Joseloff E; Balla G; Kappelmayer J; Macek M; Bell SC; Plant BJ; Amaral MD; Balogh I
J Cyst Fibros; 2019 Mar; 18(2):271-277. PubMed ID: 30268371
[TBL] [Abstract][Full Text] [Related]
12. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.
Guimbellot J; Solomon GM; Baines A; Heltshe SL; VanDalfsen J; Joseloff E; Sagel SD; Rowe SM;
J Cyst Fibros; 2019 Jan; 18(1):102-109. PubMed ID: 29685811
[TBL] [Abstract][Full Text] [Related]
15. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
[TBL] [Abstract][Full Text] [Related]
16. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
[TBL] [Abstract][Full Text] [Related]
18. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
19. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
20. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]